- Home
- AVTX vs TSBX Comparison
AVTX vs TSBX Comparison
Compare AVTX & TSBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- TSBX
- Stock Information
- Founded
- AVTX 2011
- TSBX 2015
- Country
- AVTX United States
- TSBX United States
- Employees
- AVTX N/A
- TSBX N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- TSBX
- Sector
- AVTX Health Care
- TSBX
- Exchange
- AVTX Nasdaq
- TSBX Nasdaq
- Market Cap
- AVTX 90.9M
- TSBX 11.8M
- IPO Year
- AVTX 2015
- TSBX 2023
- Fundamental
- Price
- AVTX $9.47
- TSBX $0.47
- Analyst Decision
- AVTX Buy
- TSBX Strong Buy
- Analyst Count
- AVTX 1
- TSBX 2
- Target Price
- AVTX $35.00
- TSBX $6.88
- AVG Volume (30 Days)
- AVTX 13.2K
- TSBX 138.1K
- Earning Date
- AVTX 11-07-2024
- TSBX 11-07-2024
- Dividend Yield
- AVTX N/A
- TSBX N/A
- EPS Growth
- AVTX N/A
- TSBX N/A
- EPS
- AVTX N/A
- TSBX N/A
- Revenue
- AVTX $807,000.00
- TSBX N/A
- Revenue This Year
- AVTX N/A
- TSBX N/A
- Revenue Next Year
- AVTX N/A
- TSBX N/A
- P/E Ratio
- AVTX N/A
- TSBX N/A
- Revenue Growth
- AVTX N/A
- TSBX N/A
- 52 Week Low
- AVTX $3.95
- TSBX $0.48
- 52 Week High
- AVTX $45.12
- TSBX $5.75
- Technical
- Relative Strength Index (RSI)
- AVTX 51.19
- TSBX 17.78
- Support Level
- AVTX $8.49
- TSBX $0.58
- Resistance Level
- AVTX $10.20
- TSBX $0.70
- Average True Range (ATR)
- AVTX 0.66
- TSBX 0.05
- MACD
- AVTX 0.11
- TSBX 0.03
- Stochastic Oscillator
- AVTX 60.75
- TSBX 0.16
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About TSBX Turnstone Biologics Corp.
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.